Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacia Corp. a future biotech powerhouse? -- Ignore unavailable to you. Want to Upgrade?

To: Jack Hartmann who wrote (33)	5/23/2001 4:41:16 PM
From: Jack Hartmann	Read Replies (1) \| Respond to of 35

Pharmacia (PHA) 49.37 -0.13: Prudential initiates coverage with a STRONG BUY rating and a 12-month price target of $63; says PHA should have superior earnings growth through 2004 (firm forecasts 18% annually), well ahead of the group average, combined with low patent exposure; major focus remains anti-arthritic, Celebrex (2000 sales $2.6 bln, up 78%), growth of which should pull up company-wide margins; by 2004, PHA could have three other products with annual sales over $1 bln.